Frontiers in immunology · 2026
Radiotherapy combined with immunotherapy achieves clinical complete response in elderly metastatic penile cancer: a case report.
Клинический случайСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Huang Guizhen, Li Yanghui, Li Su, Gong Long, Chen Hongtao, Li Xianming, Liao Guixiang
Аннотация
BACKGROUND: A combination of local and systemic therapies is used to treat inguinal lymph node metastases post-penile cancer surgery. This multimodal approach may include surgery, chemotherapy, radiotherapy, and immunotherapy.
CASE SUMMARY: We describe an 89-year-old male with a history of penile cancer status post resection, who presented with multiple metastases to the left inguinal lymph nodes confirmed by pathological biopsy. The patient was treated with a combination of radiotherapy and Pembrolizumab. Following this combined modality therapy, he experienced symptomatic relief and achieved a progression-free survival exceeding 38 months.
CONCLUSION: This case suggests that concurrent radiotherapy plus Pembrolizumab may achieve durable remission in elderly, chemotherapy-intolerant, metastatic PSCC, but verification in more patients is needed.
CASE SUMMARY: We describe an 89-year-old male with a history of penile cancer status post resection, who presented with multiple metastases to the left inguinal lymph nodes confirmed by pathological biopsy. The patient was treated with a combination of radiotherapy and Pembrolizumab. Following this combined modality therapy, he experienced symptomatic relief and achieved a progression-free survival exceeding 38 months.
CONCLUSION: This case suggests that concurrent radiotherapy plus Pembrolizumab may achieve durable remission in elderly, chemotherapy-intolerant, metastatic PSCC, but verification in more patients is needed.